Malignant obstructive jaundice treated with intraluminal placement of Iodine-125 seed strands and metal stents: An analysis of long-term outcomes and prognostic features

• Published in: Brachytherapy Vol. 17; no. 4; pp. 689 - 695
• Main Authors: Ma, Jingqin, Luo, Jianjun, Gu, Junying, Liu, Qingxin, Liu, Lingxiao, Zhang, Wen, Zhang, Zihan, Yan, Zhiping
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2018
• Subjects: Intraluminal brachytherapy; Iodine-125 (125I) seed strand; Malignant obstructive jaundice; Stent; Iodine-125 (125I) seed strand; Stent; Intraluminal brachytherapy; Malignant obstructive jaundice; Iodine-125 (I) seed strand
• ISSN: 1538-4721; 1873-1449
• DOI: 10.1016/j.brachy.2018.04.001

The purpose of this study was to analyze the long-term outcomes, including safety, efficacy, and prognostic features, of intraluminal brachytherapy with Iodine-125 (125I) seed strand and stent placement for treatment of patients with malignant obstructive jaundice (MOJ). From January 2009 to December 2013, 107 consecutive patients with MOJ were treated with intraluminal placement of 125I seed strands and metal stents. A retrospective evaluation of therapeutic outcomes, including overall survival (OS), stent patency rate, complications, and prognostic features, was conducted in 101 patients. 125I seed strands and stents were all successfully implanted. The median followup time was 231 (45–1015) days, and the median OS was 394.0 (95% confidence interval: 319.1–468.9) days. The cumulative OS rates at 3, 6, 12, and 24 months were 95%, 77%, 53%, and 20%, respectively. The median stent patency period was 278.0 (95% confidence interval: 164.1–391.9) days, and cumulative patency rates at 3, 6, 12, and 24 months were 92%, 69%, 45%, and 13%, respectively. Multivariate analysis indicated that the serum conjugated/total bilirubin ≥88% before procedure (p = 0.032) and whether the patient receiving further treatment (p = 0.041) appear to be the prognostic factors of OS. There is no statistical prognostic factor for stent patency. The intraluminal placement of 125I seed strands and stents appears to be a safe and efficient therapy on MOJ. The patient with serum conjugated/total bilirubin ≥88% before procedure and receiving further treatment seems to live longer.